A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis.

We have evaluated the feasibility, toxicity, and tumour response of concurrent whole-brain radiotherapy (WBRT) and chemotherapy with cisplatin, vindesine and mitomycin in the treatment of 33 patients with brain metastasis from non-small-cell lung cancer (NSCLC). The imaging response demonstrated tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuse, K., Kamimori, T., Kawahara, M., Kodama, N., Ogawara, M., Atagi, S., Naka, N., Akira, M., Kubota, K.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063289/
https://www.ncbi.nlm.nih.gov/pubmed/9052421
_version_ 1782137305478201344
author Furuse, K.
Kamimori, T.
Kawahara, M.
Kodama, N.
Ogawara, M.
Atagi, S.
Naka, N.
Akira, M.
Kubota, K.
author_facet Furuse, K.
Kamimori, T.
Kawahara, M.
Kodama, N.
Ogawara, M.
Atagi, S.
Naka, N.
Akira, M.
Kubota, K.
author_sort Furuse, K.
collection PubMed
description We have evaluated the feasibility, toxicity, and tumour response of concurrent whole-brain radiotherapy (WBRT) and chemotherapy with cisplatin, vindesine and mitomycin in the treatment of 33 patients with brain metastasis from non-small-cell lung cancer (NSCLC). The imaging response demonstrated that 25 patients (75.8%) responded to brain lesions, including five complete responders, and the response rate to primary lesion was 18%. The treatment improved at least one grade of performance status in 30% and of neurological functions in 55% of the patients. The major toxicity was leucopenia (> or = grade 3, 84.4%). Median survival was 9.7 months and the 1-year survival rate was 40%. Concurrent WBRT and chemotherapy can be safely administered to patients with brain metastasis from NSCLC, with a remarkable response rate, improvement of neurological functions and encouraging survival duration.
format Text
id pubmed-2063289
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20632892009-09-10 A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis. Furuse, K. Kamimori, T. Kawahara, M. Kodama, N. Ogawara, M. Atagi, S. Naka, N. Akira, M. Kubota, K. Br J Cancer Research Article We have evaluated the feasibility, toxicity, and tumour response of concurrent whole-brain radiotherapy (WBRT) and chemotherapy with cisplatin, vindesine and mitomycin in the treatment of 33 patients with brain metastasis from non-small-cell lung cancer (NSCLC). The imaging response demonstrated that 25 patients (75.8%) responded to brain lesions, including five complete responders, and the response rate to primary lesion was 18%. The treatment improved at least one grade of performance status in 30% and of neurological functions in 55% of the patients. The major toxicity was leucopenia (> or = grade 3, 84.4%). Median survival was 9.7 months and the 1-year survival rate was 40%. Concurrent WBRT and chemotherapy can be safely administered to patients with brain metastasis from NSCLC, with a remarkable response rate, improvement of neurological functions and encouraging survival duration. Nature Publishing Group|1 1997 /pmc/articles/PMC2063289/ /pubmed/9052421 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Furuse, K.
Kamimori, T.
Kawahara, M.
Kodama, N.
Ogawara, M.
Atagi, S.
Naka, N.
Akira, M.
Kubota, K.
A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis.
title A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis.
title_full A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis.
title_fullStr A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis.
title_full_unstemmed A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis.
title_short A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis.
title_sort pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063289/
https://www.ncbi.nlm.nih.gov/pubmed/9052421
work_keys_str_mv AT furusek apilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT kamimorit apilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT kawaharam apilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT kodaman apilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT ogawaram apilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT atagis apilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT nakan apilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT akiram apilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT kubotak apilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT furusek pilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT kamimorit pilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT kawaharam pilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT kodaman pilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT ogawaram pilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT atagis pilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT nakan pilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT akiram pilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis
AT kubotak pilotstudyofconcurrentwholebrainradiotherapyandchemotherapycombinedwithcisplatinvindesineandmitomycininnonsmallcelllungcancerwithbrainmetastasis

Ejemplares similares